Mark B. Leick

3.5k total citations · 3 hit papers
47 papers, 1.8k citations indexed

About

Mark B. Leick is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Mark B. Leick has authored 47 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 13 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in Mark B. Leick's work include CAR-T cell therapy research (34 papers), Nanowire Synthesis and Applications (8 papers) and Immune Cell Function and Interaction (7 papers). Mark B. Leick is often cited by papers focused on CAR-T cell therapy research (34 papers), Nanowire Synthesis and Applications (8 papers) and Immune Cell Function and Interaction (7 papers). Mark B. Leick collaborates with scholars based in United States, United Kingdom and Netherlands. Mark B. Leick's co-authors include Marcela V. Maus, Matthew J. Frigault, Bryan D. Choi, Amanda A. Bouffard, Rebecca C. Larson, Stefanie R. Bailey, Bob S. Carter, William T. Curry, Andrea Schmidts and Irene Scarfò and has published in prestigious journals such as Nature, New England Journal of Medicine and Nature Communications.

In The Last Decade

Mark B. Leick

41 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

2019 426 citations Bryan D. Choi, Xiaoling Yu et al. Nature Biotechnology profile →
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

2022 225 citations Rebecca C. Larson, Michael C. Kann et al. Nature profile →
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma

2024 210 citations Bryan D. Choi, Matthew J. Frigault et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark B. Leick United States	16	1.4k	526	518	505	408	47	1.8k
Jamie R. Wagner United States	11	1.5k 1.0×	410 0.8×	625 1.2×	570 1.1×	476 1.2×	28	1.8k
Biagio De Angelis Italy	22	1.2k 0.8×	543 1.0×	774 1.5×	326 0.6×	352 0.9×	44	1.7k
Selene Nuñez-Cruz United States	18	1.1k 0.8×	584 1.1×	891 1.7×	365 0.7×	322 0.8×	35	1.9k
Nicholas Tschernia United States	7	2.1k 1.5×	590 1.1×	614 1.2×	558 1.1×	656 1.6×	20	2.3k
Rebecca Gardner United States	13	1.8k 1.3×	514 1.0×	446 0.9×	504 1.0×	592 1.5×	23	2.1k
Reed M. Hawkins United States	8	1.4k 1.0×	479 0.9×	465 0.9×	344 0.7×	399 1.0×	17	1.6k
Elad Jacoby Israel	22	1.5k 1.1×	818 1.6×	528 1.0×	335 0.7×	505 1.2×	76	2.2k
Rosalie M. Sterner United States	11	1.4k 1.0×	676 1.3×	805 1.6×	492 1.0×	342 0.8×	22	2.1k
Ignazio Caruana Italy	18	1.4k 1.0×	556 1.1×	709 1.4×	488 1.0×	496 1.2×	35	1.8k

Countries citing papers authored by Mark B. Leick

Since Specialization

Citations

This map shows the geographic impact of Mark B. Leick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark B. Leick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark B. Leick more than expected).

Fields of papers citing papers by Mark B. Leick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark B. Leick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark B. Leick. The network helps show where Mark B. Leick may publish in the future.

Co-authorship network of co-authors of Mark B. Leick

This figure shows the co-authorship network connecting the top 25 collaborators of Mark B. Leick. A scholar is included among the top collaborators of Mark B. Leick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark B. Leick. Mark B. Leick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bouffard, Amanda A., Mark B. Leick, Nicholas J. Haradhvala, et al.. (2025). On-target off-tumor toxicity of claudin18.2-directed CAR-T cells in preclinical models. Nature Communications. 16(1). 9650–9650.

Park, Sangwoo, Christine Ho, Eli P. Darnell, et al.. (2025). Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. Nature Communications. 16(1). 11246–11246.

Grauwet, Korneel, Trisha R. Berger, Michael C. Kann, et al.. (2024). Stealth transgenes enable CAR-T cells to evade host immune responses. Journal for ImmunoTherapy of Cancer. 12(5). e008417–e008417. 8 indexed citations

Korell, Felix, Michael Olson, Diego Salas‐Benito, et al.. (2024). Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics. Science Translational Medicine. 16(750). eadk7640–eadk7640. 14 indexed citations

Lee, Won‐Ho, Charlotte Graham, Felix Korell, et al.. (2024). Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood. Cytometry Part B Clinical Cytometry. 106(3). 162–170.

Silva, Harrison, Marc Wehrli, Michael C. Kann, et al.. (2024). CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML. Blood. 145(7). 720–731. 11 indexed citations

Graham, Charlotte, Won‐Ho Lee, Mark B. Leick, et al.. (2023). Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity. Blood. 142(14). 1248–1252. 32 indexed citations

Kann, Michael C., Emily M. Schneider, Amanda A. Bouffard, et al.. (2023). Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7. Leukemia. 38(3). 590–600. 4 indexed citations

Boucher, Justin C., Bishwas Shrestha, Mark B. Leick, et al.. (2023). Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Molecular Therapy — Oncolytics. 31. 100751–100751. 21 indexed citations

10.

Kembuan, Gabriele, Michael C. Kann, William M. Lin, et al.. (2023). Genetic retargeting of E3 ligases to enhance CAR T cell therapy. Cell chemical biology. 31(2). 338–348.e5. 7 indexed citations

11.

Larson, Rebecca C., Michael C. Kann, Stefanie R. Bailey, et al.. (2022). CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 604(7906). 563–570. 225 indexed citations breakdown →

12.

Leick, Mark B. & Yi‐Bin Chen. (2022). Paraneoplastic Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine. 205(12). e55–e55. 1 indexed citations

13.

Leick, Mark B., Harrison Silva, Irene Scarfò, et al.. (2022). Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 40(5). 494–508.e5. 88 indexed citations

14.

Schmidts, Andrea, Amanda A. Bouffard, Angela C. Boroughs, et al.. (2020). Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources. Journal for ImmunoTherapy of Cancer. 8(2). e000990–e000990. 18 indexed citations

15.

Leick, Mark B., Marcela V. Maus, & Matthew J. Frigault. (2020). Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies. Molecular Therapy. 29(2). 433–441. 22 indexed citations

16.

Leick, Mark B., Rachel M. Gittelman, Erik Yusko, et al.. (2020). T Cell Clonal Dynamics Determined by High-Resolution TCR-β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 26(9). 1567–1574. 15 indexed citations

17.

Frigault, Matthew J., Jörg Dietrich, María Martínez-Lage, et al.. (2019). Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 134(11). 860–866. 160 indexed citations

18.

Choi, Bryan D., Xiaoling Yu, Ana P. Castaño, et al.. (2019). CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nature Biotechnology. 37(9). 1049–1058. 426 indexed citations breakdown →

19.

Leick, Mark B., Bradley D. Hunter, Zachariah DeFilipp, et al.. (2019). Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases. Bone Marrow Transplantation. 55(4). 758–762. 6 indexed citations

20.

Tsimberidou, Apostolia M., Mark B. Leick, JoAnn Lim, et al.. (2012). Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemotherapy and Pharmacology. 71(2). 389–397. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact